Snowball logo
logo
RVLP

RVL Pharmaceuticals PLC

-- $$0.00  (0%)
Estimate
EPS
-0.71
Growth
Revenue, YoY
-2.25%
Net income, YoY
-97.33%
FCF, YoY
-756.71%
Forecast
EPS (FWD)
-0.3
About the company
Ticker
RVLP
ISIN
IE00BF2HDL56
Country
United States of America
Sector (GICS)
Healthcare
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

Frequently asked questions

What sector does RVL Pharmaceuticals PLC (RVLP) operate in?

RVL Pharmaceuticals PLC belongs to the Healthcare sector and operates in the Biotechnology industry.

What is RVL Pharmaceuticals PLC (RVLP) Earnings Per Share (EPS)?

The trailing EPS is -$0.71, and the forward EPS is -$0.30.

What is RVL Pharmaceuticals PLC (RVLP) EBITDA?

RVL Pharmaceuticals PLC EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -7.66 million.

Does RVL Pharmaceuticals PLC (RVLP) pay dividends?

No. RVL Pharmaceuticals PLC does not pay a dividend.

How did RVL Pharmaceuticals PLC (RVLP) perform in its most recent earnings report?

In the last report (September 30, 2023), RVL Pharmaceuticals PLC posted an EPS surprise of -118.18% and a revenue surprise of -22.24%.

When is RVL Pharmaceuticals PLC (RVLP) next earnings report?

RVL Pharmaceuticals PLC is expected to release its next earnings report on December 31, 2023.